Respira Therapeutics, Inc. ayaa maanta ku dhawaaqday in bukaan-socodka ugu horreeya ee Maraykanka lagu darey tijaabinta xarumaha badan ee musharaxa alaabta rasaasta, RT234-PAH (vardenafil oo loo maamulo sida budada qallalan ee la nuugo). Tijaabada VIPAH-PRN 2b (Vardenafil Inhaled for Pulmonary Arterial Hypertension - PRN) waxay ka koobnaan doontaa laba kooxood oo isku xigta oo helaya RT234 sida hal qiyaas oo lagu maamulo Axial Oscillating Sphere inhaler qalalan. Daraasada waxaa loogu talagalay in lagu qiimeeyo badbaadada iyo waxtarka horudhaca ah ee RT234 si aad u wanaajiso calaamadaha episodic iyo awoodda jimicsiga ee dadka lagu daweynayo dhiig-karka sambabada ee sambabada (PAH) oo leh New York Heart Association (NYHA) Calaamadaha Fasalka II-III.
"Bilawga tijaabadan caafimaad waxay u taagan tahay guul muhiim ah oo loogu talagalay Respira waana tallaabada xigta ee muhiimka ah ee suurtogalka ah in la siiyo bukaannada qaba PAH daaweyn degdeg ah si ay u maareeyaan neefta gaaban, taas oo ka hortagaysa inay gutaan waajibaadkooda maalinlaha ah," ayuu yiri Carol Satler, PhD. , MD, Madaxweynaha iyo Madaxa Caafimaadka ee Respira. "Dadka la ildaran xaaladdan daciifka ah iyo xaaladdan halista ah ee lagu daweynayo daawaynta dayactirka ayaa weli la kulma xaaladaha neefta oo gaaban, daal iyo awood la'aanta jimicsiga, mana jiraan hadda daawayn degdeg ah oo loo heli karo 'sida loo baahan yahay' si loo yareeyo dhacdooyinkan. ”
"U oggolaanshaha bukaannada PAH inay noqdaan kuwo firfircoon ayaa fure u ah caafimaadkooda jireed iyo maskaxeed," ayuu yiri Raymond L. Benza, MD, Agaasimaha Qeybta Daawada Wadnaha ee Jaamacadda Gobolka Ohio ee Wexner Medical Center. "Hadda daraasadda RT234, waxaan baaraynaa awoodda aan u leenahay inaan kor u qaadno dhaqdhaqaaqa jireed marka bukaanku u baahdo. Waxay suurtogal u tahay tallaabo weyn oo hore loo qaaday dagaalka aan kula jirno cudurkan."
Tijaabada VIPAH-PRN 2b (RT234-PAH-CL202) waa daraasad-kordhinta qiyaasta si loo qiimeeyo isbeddellada ba'an ee calaamadaha ka dib qiyaasta RT234 ee maadooyinka PAH. Waxaa la qiyaasaa in la neefsado RT234 (budada neefta vardenafil) waxay ku siin kartaa faa'iido daweyn oo loogu talagalay isticmaalka degdega ah ee bukaanada qaba Ururka Caafimaadka Adduunka (WHO) Kooxda 1 Dhiig-karka Sambabada (PH) (Pulmonary arterial hypertension [PAH]) si loo hagaajiyo awoodda jimicsiga iyo waxqabadka Dhaqdhaqaaqyada nolol maalmeedka, iyo sidoo kale waxay yareeyaan calaamadaha dhaqdhaqaaqa (tusaale, dyspnea) iyo saameyntooda xun ee tayada nolosha.
